The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| NWBO | -22.26% | -82.43% | -29.37% | -100% |
| S&P | +14.49% | +91.09% | +13.83% | +510% |
Northwest Biotherapeutics, Inc. is a biotechnology company, which engages in the development of personalized immune therapies for cancer. It offers DCVax technology platform, which uses activated dendritic cells to mobilize a patient’s own immune system to attack their cancer. The company was founded by Alton L. Boynton on March 18, 1996 and is headquartered in Bethesda, MD.
In a short period of time, this immunotherapy biotech could either become a multi-bagger or trade near $0.
Will a 14-year clinical trial evaluating an immunotherapy for the most lethal form of brain cancer have a positive outcome?
| Q2 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.13M | -74.3% |
| Gross Profit | -$0.39M | -6333.3% |
| Gross Margin | -294.66% | -293.5% |
| Market Cap | $345.85M | -33.1% |
| Market Cap / Employee | $13.83M | 0.0% |
| Employees | 25 | 13.6% |
| Net Income | -$15.38M | 13.9% |
| EBITDA | -$14.26M | 15.8% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q2 2025 | YOY Change | |
|---|---|---|
| Net Cash | $4.32M | 49.8% |
| Inventory | 0 | 0.0% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $27.56M | 11.2% |
| Short Term Debt | $42.25M | 37.3% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -284.20% | -24.9% |
| Return On Invested Capital | 106.89% | 23.9% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$6.99M | 58.2% |
| Operating Free Cash Flow | -$6.69M | 58.7% |
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | -5.15 | -4.42 | -3.21 | -3.36 | -51.82% |
| Price to Sales | 252.34 | 256.05 | 210.80 | 315.38 | 0.10% |
| Price to Tangible Book Value | -5.02 | -4.31 | -3.15 | -3.29 | -51.49% |
| Enterprise Value to EBITDA | -33.20 | -24.15 | -23.28 | -29.75 | -14.51% |
| Total Debt | $58.34M | $67.44M | $69.01M | $69.81M | 25.61% |
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
